NIH Selects T Cell-Priming Vaccine Candidate to be Included in Clinical Trials Under Project NextGen
Emergex’s T cell-priming candidate will be studied in early-phase trials in search for next generation of COVID-19 vaccines.
Emergex Vaccines has announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has selected its T cell-priming vaccine candidate against Betacoronaviruses for inclusion in Project NextGen. Emergex’s vaccine candidate will be evaluated alongside other potential candidates in early-phase trials to find the next generation of COVID-19 vaccines.1
In a press release, Professor Thomas Rademacher, co-founder and chief executive officer, Emergex said, “We are thrilled that our immunotherapy candidate for Betacoronaviruses, which has already demonstrated an excellent safety profile and shown to be capable of eliciting targeted CD8 T cell immune memory, has been selected as part of the Project NextGen initiative. Our T cell-based platform technology has the potential to address current and future coronavirus challenges and thereby strengthen preparedness for future pandemics, through harnessing the natural course of cellular immunity by ensuring rapid, targeted and robust immune responses against emerging infectious threats.”
In July 2023, Emergex shared promising data from a completed Phase I trial of CoronaTcP, its multi-target T cell-priming set-point product designed to be effective against Betacoronaviruses, including SARS-CoV-1 and emerging variants of SARS-CoV-2.2
Results showed CoronaTcP demonstrated a favorable safety profile and the ability to induce epitope-specific CD8+ memory subsets, which are critical for long-lasting protection against Betacoronaviruses.
The Phase I trial, naNO-COVID (NCT05113862), was a double-blind, randomized, base particle-controlled, single center study evaluating the safety and reactogenicity of two intradermal injections of CoronaTcP at two different dosages. Based in Switzerland, the trial enrolled 26 adult participants previously vaccinated against SARS-CoV-2.
In an earlier press release, Rademacher said, “The positive data from both clinical trials—naNO-DENGUE and naNO-COVID—represent an important landmark for Emergex. Demonstrating that our platform has an acceptable safety profile and successfully mobilizes specific T cells that may elicit broad and long-term immune memory, validates our approach. By improving T cell-based immunity, we can enhance any previous immune status. We are delighted that this first assessment of a treatment against infectious diseases for clinical use, based solely on a T cell response, was successful.”
Project NextGen is well underway. In June, the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS) announced up to $500 million in Project NextGen funding to evaluate novel vaccines against COVID-19.3
“At ASPR, we are working to unlock technology that will better protect Americans from viruses like COVID-19,” Dawn O'Connell, assistant secretary for preparedness and response, HHS, said in a press release. “The next generation vaccines that BARDA is investing in may bolster our protection against COVID-19 and be easier to administer through intranasal or oral delivery.”
References
1. Emergex T Cell-Priming Vaccine Candidate for Betacoronaviruses selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials. News release. Emergex. October 2, 2024. Accessed October 7, 2024. https://emergexvaccines.com/emergex-t-cell-priming-vaccine-candidate-for-betacoronaviruses-selected-by-nih-niaid-project-nextgen-for-inclusion-in-clinical-trials/
2. Emergex Reports Promising Data from Completed Swiss Phase I Trial of CoronaTcP™, T Cell-Priming Immune Set-Point Candidate for Betacoronaviruses. News release. Emergex. July 19, 2023. Accessed October 7, 2024. https://emergexvaccines.com/emergex-reports-promising-data-from-completed-swiss-phase-i-trial-of-coronatcp-t-cell-priming-immune-set-point-candidate-for-betacoronaviruses/
3. BARDA awards up to $500 million in Project NextGen funding for vaccine clinical trials. News release. US Department of Health and Human Services. June 13, 2024. Accessed October 7, 2024. https://www.hhs.gov/about/news/2024/06/13/barda-awards-500-million-project-nextgen-funding-vaccine-clinical-trials.html
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
